Skip to main content
AmigoFish

Big announcement and Hepatic impairment studies (Ep. 22)

From Clinical Pharmacology Podcast with Nathan Teuscher · · 18 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Today’s show is about hepatic impairment clinical studies. I cover the rationale behind evaluating hepatic impairment, common study designs, and key factors in the analysis and interpretation of the study results. I also share a huge announcement about Aplos NCA, a cloud-based solution for calculating NCA PK parameters. Use the link below to learn more about Aplos NCA.

Links discussed in the show:

- FDA guidance (https://go.teuschersolutions.com/hepaticfda)

- EMA guideline (https://go.teuschersolutions.com/hepaticema)

- Aplos Analytics website (https://aplosanalytics.com)

- You can connect with me on LinkedIn (https://go.teuschersolutions.com/linkedin) and send me a message

- Send me a message (https://go.teuschersolutions.com/contact)

- Sign up for my newsletter (https://go.teuschersolutions.com/newsletter)

Copyright Teuscher Solutions LLC

Back to Clinical Pharmacology Podcast with Nathan Teuscher · Report a problem